Company Profile

Integra Holdings is a unique healthcare investment company, with an exclusive right to first examine the most promising innovations and IP emerging from the world renowned Hebrew University of Jerusalem.

With a focus on biopharmaceuticals and medical diagnostics and devices, Integra employs multidisciplinary teams of experts who work alongside inventors and take a hands-on approach to achieving commercial success. We provide know-how and support to our portfolio companies from inception to commercialization, while leveraging our extensive industry network cultivated over decades.

Integra Holdings was founded in 2012 by Yissum, the distinguished technology transfer company of the Hebrew University of Jerusalem. Shareholders include Temasek, Invatech Holdings, The Israeli Teachers and Kindergarten funds, Halman-Aldubi Investment Group, the HU Provident fund, ZongHeng Group and Arie Capital.

Integra Holdings holds a diversified portfolio of eleven companies in early to late stages – with established partnerships with leading investment funds such as Orbimed, Pontifax, Lundbeck fund, SROne, CBI and Biolight LifeSciences, as well as private investors.

The Hebrew University of Jerusalem

The Hebrew University of Jerusalem is widely recognized for its long-standing leading record of academic excellence. Ranked among the 100 top universities in the world and first among Israeli universities, its rich history of achievements include 8 Nobel Prizes, 269 Israel Prizes and 9 Wolf Prizes, among others. Established in 1918, its first Board of Governors included Sigmund Freud, Martin Buber and Albert Einstein.

The Hebrew University has an outstanding medical tradition, with 5 out of its 17 schools and faculties relating to healthcare. The numbers speak for themselves:

  • 43% of Israel’s biotechnology research
  • Six campuses and five affiliated hospitals
  • 1,600 biotechnology post-graduate students
  • 33% of all Israeli PhD candidates
  • 400 applied sciences researchers
  • 3,500 research projects